Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by ADC Therapeutics SA < Previous 1 2 3 Next > ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma September 16, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes August 15, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates August 09, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022 August 02, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors July 27, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma July 20, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial July 11, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories July 08, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors July 01, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents June 29, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer June 13, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics to Present at the Jefferies Healthcare Conference June 01, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress May 12, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates May 09, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Announces CEO Transition May 09, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference May 04, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022 May 03, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services April 04, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021 March 17, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022 February 24, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report February 17, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline February 08, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics to Participate in Guggenheim Oncology Conference February 02, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan January 18, 2022 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting November 04, 2021 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates November 02, 2021 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA® October 29, 2021 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021 October 27, 2021 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors September 27, 2021 From ADC Therapeutics SA Via Business Wire Tickers ADCT ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference September 23, 2021 From ADC Therapeutics SA Via Business Wire Tickers ADCT < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.